A Single Nucleotide Polymorphism in the Plasma PAF Acetylhydrolase Gene and Risk of Atherosclerosis in Japanese Patients With Peripheral Artery Occlusive Disease

Journal of Surgical Research

Volumn 134, Issue 1, 2006, Pages 36-43

  Unno, Naoki ^a   Sakaguchi, Takanori ^a   Nakamura, Toshio ^a   Yamamoto, Naoto ^a   Sugatani, Junko ^b   Miwa, Masao ^b   Konno, Hiroyuki ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF SHIZUOKA   (Japan)

Author keywords

atherosclerosis; cholesterol; lipoprotein; PAF acetylhydrolase; peripheral artery occlusive disease

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; CHOLESTEROL; GENOMIC DNA; HIGH DENSITY LIPOPROTEIN; LIPID; LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ALLELE; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CHOLESTEROL BLOOD LEVEL; COMORBIDITY; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; DNA DETERMINATION; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME DEFICIENCY; FEMALE; FREQUENCY ANALYSIS; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE; HUMAN; HYPERCHOLESTEROLEMIA; JAPAN; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MUTATION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL SIGNIFICANCE; STROKE; VASCULAR SURGERY;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; AGED; ARTERIAL OCCLUSIVE DISEASES; ATHEROSCLEROSIS; CASE-CONTROL STUDIES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; PERIPHERAL VASCULAR DISEASES; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 33745005896     PISSN: 00224804     EISSN: 10958673     Source Type: Journal    
DOI: 10.1016/j.jss.2006.02.058     Document Type: Article

References (43)

1. Camussi G.A.M., Coda R., Bussolino F., Piacibello W., and Tetta C. Release of platelet-activating factor (PAF) and histamine. II. The cellular origin of human PAF: Monocytes, polymorphonuclear neutrophils and basophils. Immunology 42 (1981) 191
2. Montrucchio G., Lupia E., De Martino A., et al. Plasmin promotes an endothelium-dependent adhesion of neutrophils. Involvement of platelet activating factor and P-selectin. Circulation 93 (1996) 2152
3. Tselepis A.D., Tsoukatos D., Droudes C., Donas A., and Evangelou A. Platelet response to the aggregatory effects of platelet activating factor(PAF) ex vivo in patients with acute myocardial infarction. Eur J Clin Invest 21 (1991) 490
4. Prescott S.M., McIntyre T.M., Zimmerman G.A., and Stafforini D.M. Inflammation as an early component of atherosclerosis and vascular damage. A role for P-selectin and platelet-activating factor. Jpn Circ J 60 (1996) 137
5. Mueller H.W., Haught C.A., McNatt J.M., et al. Measurement of platelet-activating factor in a canine model coronaly thrombosis and in endarterectomy samples from patients with advanced coronary artery disease. Circ Res 71 (1995) 54
6. Tjoelker L.W., Wilder C., Eberhardt C., et al. Anti-inflammatory properties of a platelet-activating factor acetylhydrolase. Nature 374 (1995) 549
7. Miwa M., Miyake T., Yamanaka T., et al. Characterization of serum platelet-activating factor (PAF) acetylhydrolase. Correlation between deficiency of serum PAF acetylhydrolase and respiratory symptoms in asthmatic children. J Clin Invest 82 (1988) 1983
8. Stafforini D.M., Satoh K., Atkinson D.L., et al. Platelet-activating factor acetylhydrolase deficiency. A missense mutation near the active site of an anti-inflammatory phospholipase. J Clin Invest 97 (1996) 2784
9. Xu H., Iijima K., Shiozawa S., et al. Platelet-activating factor acetylhydrolase gene mutation in Japanese nephrotic children. Kidney Int 54 (1998) 1867
10. Minami T., Suzuki H., Takeuchi T., Uemura S., Sugatani J., and Yoshikawa N. A polymorphism in plasma platelet-activating factor acetylhydrolase is involved in resistance to immunoglobulin treatment in Kawasaki disease. J Pediatr 147 (2005) 78
11. -T missence mutation in exon 9 of the plasma platelet-activating factor acetylhydrolase gene as an independent risk factor for coronary artery disease in Japanese men. Metabolism 47 (1998) 177
12. 279 - Phe) is a genetic risk factor for stroke. Stroke 28 (1997) 2417
13. Yamada Y., and Yokota M. Loss of activity of plasma platelet-activating factor acetylhydrolase due to a novel Gln281 → Arg mutation. Biochem Biophys Res Commun 236 (1997) 772
14. Kruse S., Mao X.Q., Heinzmann A., et al. The Ile198Thr and Ala379Val variants of plasmatic PAF-acetylhydrolase impair catalytical activities and are associated with atopy and asthma. Am J Hum Genet 66 (2000) 1522
15. Unno N., Nakamura T., Kaneko H., et al. Plasma platelet-activating factor acetylhydrolase deficiency is associated with atherosclerotic occlusive disease in Japan. J Vasc Surg 32 (2000) 263
16. Society J.A. Guideline for diagnosis and treatment of hyperlipidemias. Atherosclerosis (Japan) 25 (1997) 1
17. Packard C.J., O'Reilly D.S.J., Caslake M.J., et al. Lipoporotein-associated phospholipase A2 as an independent predictor of coronary heart disease. N Engl J Med 343 (2000) 1148
18. Winkler K., Winkelmann B.R., Scharnagl H., et al. Platelet-activating factor acetylhydrolase activity indicates angiographic coronary artery disease independently of systemic inflammation and other risk factors. The Ludwigshafen Risk and Cardiovascular Health Study. Circulation 111 (2005) 980
19. Yamada Y., Yoshida H., Ichihara S., Imaizumi T., Satoh K., and Yokota M. Correlations between plasma platelet-activating factor acetylhydrolase (PAF-AH) activity and PAF-AH genotype, age, and atherosclerosis in a Japanese population. Atherosclerosis 150 (2000) 209
20. Berliner J.A., Navab M., Fogelman A.M., et al. Atherosclerosis. Basic mechanism oxidation, inflammation, and genetics. Circulation 91 (1995) 2488
21. Aikawa M., Rabkin E., Okada Y., et al. Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabit atheroma. A potential mechanism of lesion stabilization. Circulation 97 (1998) 2433
22. Steinberg D. Low density lipoprotein oxidation and its pathobiological significance. J Biol Chem 272 (1997) 17895
23. Macphee C.H., Moores J.E., Dhanak D., et al. Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein. Use of a novel inhibitor. Biochemical J 338 (1999) 479
24. Marathe G.K., Silva A.R., de Castro Faria Neto H.C., et al. Lysophosphatidylcholine and lyso-PAF display PAF-like activity derived from contaminating phospholipids. J Lipid Res 42 (2001) 1430
25. Chen C.H. Platelet-activating factor acetylhydrolase. Is it good or bad for you?. Curr Opin Lipidol 15 (2004) 337
26. Watson A.D., Navab M., and Hama S.Y. Effect of platelet activating factor-acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein. J Clin Invest 95 (1995) 774
27. Chang P.Y., Luo S., Jiang T., et al. Oxidized low-density lipoprotein downregulates endothelial basic fibroblast growth factor through a pertussis toxin-sensitive G-protein pathway. Circulation 104 (2001) 588
28. Lee C., Sigari F., Horkko S., et al. All apoB-containing lipoproteins induce monocyte chemotaxis and adhesion when minimally modified modulation of lipoprotein bioactivity of lipoprotein bioactivity by platelet-activating factor acetylhydrolase. Arterioscler Thromb Vasc Biol 19 (1999) 1437
29. Quarck R., De Geest B., Stengel D., et al. Adenovirus-mediated gene transfer of human platelet-activating factor-acetylhydrolase prevents injury-induced neointima formation and reduces spontaneous atherosclerosis in apolipoprotein E-deficient mice. Circulation 103 (2001) 2495
30. Arakawa H., Qian J.Y., Baatar D., et al. Local expression of platelet-activating factor-acetylhydrolase reduces accumulation of oxidized lipoproteins and inhibits inflammation, shear stress-induced thrombosis, and neointima formation in balloon-injured carotid arteries in nonhyperlipidemic rabbits. Circulation 111 (2005) 3302
31. Guerra R., Zhao B., Mooser V., Stafforini D., Johnston J.M., and Cohen J.C. Determinants of plasma platelet-activating factor acetylhydrolase. Heritability and relationship to plasma lipoproteins. J Lipid Res 38 (1997) 2281
32. Karabina S.A.P., Elisaf M., Bairaktari E., Tzallas C., Siamopoulos K.C., and Tselepis A.D. Increased activity of platelet-activating factor acetylhydrolase in low-density lipoprotein subfractions induces enhanced lysophosphatidylcholine production during oxidation in patients with heterozygous familial hypercholesterolaemia. Eur J Clin Invest 27 (1997) 595
33. Hakkinen T., Luoma J.S., Hiltunen M.O., et al. Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, is expressed by macrophages in human and rabbit atherosclerotic lesion. Arterioscler Thromb Vasc Biol 19 (1999) 2909
34. Memon R.A., Fuller J., Moser A.H., Feingold K.R., and Grunfeld C. In vivo regulation of plasma platelet-activating factor acetylhydrolase during the acute phase response. Am J Physiol 277 (1999) R94
35. Stafforini D.M., Elstad M.R., McIntyre T.M., Zimmerman G.A., and Prescott S.M. Human macrophages secrete platelet-activating factor acetylhydrolase. J Biol Chem 265 (1990) 9682
36. Corl C.M., Cao Y.Z., Cohen Z.S., and Sordillo L.M. Oxidant stress enhances Lyso-PAF-AcT activity by modifying phospholipase D and phosphatidic acid in aortic endothelial cells. Biochem Biophys Res Commun 302 (2003) 610
37. Stafforini D.M., McIntyre T.M., Carter M.E., and Prescott S.M. Human plasma platelet-activating factor acetylhydrolase. J Biol Chem 262 (1987) 4215
38. Gordon T., Castelli W.P., Hjortland M.C., Kannel W.B., and Dawber T.R. High density lipoprotein as aprotective factor against coronary heart disease. The Framingham Study. Am J Med 62 (1977) 707
39. Miller N.E., La Ville A., and Crook D. Direct evidence that reverse cholesterol transport is mediated by high-density lipoprotein in rabbit. Nature 314 (1985) 109
40. Cockerill G.W., Rye K.A., Gamble J.R., Vadas M.A., and Barter P.J. High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler Thromb Vasc Biol 15 (1995) 1987
41. -/- mice. FASEB J 14 (2000) 2032 2000
42. Ehara S., Ueda M., Naruko T., et al. Elevated levels of oxidized low density lipoprotein show a positive relationship with severity of acute coronary syndromes. Circulation 103 (2001) 1955
43. Balta G., Gurgey A., Kudayarov D.K., Tunc B., and Altay C. Evidence for the existence of the PAF acetylhydrolase mutation (Val279Phe) in non-Japanese populations. A preliminary study in Turkey, Azerbaijan, and Kyrgyzstan. Thromb Res 101 (2001) 231